Previous Close | 3.2350 |
Open | 3.3100 |
Bid | 2.9700 x 1000 |
Ask | 3.1000 x 800 |
Day's Range | 2.9800 - 3.3100 |
52 Week Range | 1.5000 - 8.9910 |
Volume | |
Avg. Volume | 20,930 |
Market Cap | 48.72M |
Beta (5Y Monthly) | -0.22 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.5350 |
Earnings Date | Mar 23, 2022 - Mar 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 13.50 |
HANOVER, MD, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a conference call and live webcast on August 11, 2022, at 4:30 p.m. EST to discuss its second quarter 2022 results and provide an update on its clinical pipeline. Conference Call Information To participate in this
HANOVER, MD, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, announces today that it has launched a new website Necrobiosislipoidicastudy.com. The website is designed to increase awareness of ulcerative Necrobiosis Lipoidica (“uNL”), an extremely rare condition, and to inf
HANOVER, MD, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical need conditions, announces today that it has launched a new website Necrobiosislipoidicastudy.com. The website is designed to increase awareness of ulcerative Necrobiosis Lipoidica (“uNL”), an extremely rare condition, and to inf